CorMedix REZZAYO Phase III Prophylaxis Data Positive, Supports Diversification Thesis

What happened

CorMedix announced positive topline results from the Phase III ReSPECT trial, meeting the primary endpoint of non-inferiority in fungal-free survival versus standard antimicrobial regimen in allogeneic hematopoietic stem cell transplant patients. This de-risks a key pipeline catalyst and expands REZZAYO's potential beyond its current approved use in dialysis patients, supporting management's narrative of a broader hospital anti-infective platform. The data partially offsets concerns about the upcoming July 2026 DefenCath reimbursement reset by providing an additional growth vector. However, the trial demonstrated non-inferiority, not superiority, and the addressable patient population is relatively niche, limiting near-term revenue impact. Future label expansion and market adoption remain to be proven through regulatory filings and commercial execution.

Implication

The success validates REZZAYO's potential as a second growth leg beyond the dialysis TDAPA cliff, but efficacy and market uptake will take time to materialize. It increases confidence in the bull case (20% probability, $12.50) but does not alter FY2026 estimates. The near-term thesis still hinges on DefenCath volume growth and Melinta synergy execution.

Thesis delta

The positive REZZAYO prophylaxis data strengthens the bull case probability and reduces downside risk from pipeline failure. However, the near-term thesis still hinges on DefenCath volume growth ahead of the July 2026 reimbursement reset. The catalyst is confirmatory rather than transformative for FY2026 estimates, which already assumed a positive readout in the bull scenario.